PATENT CLAIM ANALYSIS

Application Number: 16091451
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "641000"]

Abstract:
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic acid (20:5; EPA), or esters thereof, and (iii) choline, or salts or esters thereof, in the manufacture of a product for therapeutically improving language development and reducing language skills impairment in children with suspected or confirmed cerebral palsy, or children at risk thereof.

Claim (Index 33):
The method according to  claim 27 , wherein the child at risk of cerebral palsy was born preterm and small for gestational age; or born preterm with brain injury; or born term but small for gestational age; or born term with brain injury, or born preterm and small for gestational age with brain injury or born term but small for gestational age with brain injury.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.72414
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15417943', '14005098', '15770116', '15115487', '14421432']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7422533300607859
- 35 USC 102 Novelty (BERT): 0.5196507975925453
- Combined Prediction Score: 0.7199930768139619
- Mean Citation Score: 222.142574
- Max Citation Score: 235.74988
- Similarity Product: 119.47808037260056

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test